Abstract 2935
Background
Overall survival (OS) has become the definitive endpoint in oncology clinical trials, but may be difficult to assess due to need for lengthy follow-up, factors related to trial design or impacted by study crossover. Progression free survival (PFS) is a common primary endpoint, but, differential response to subsequent therapy may affect the correlation of PFS and OS. The European Medicines Agency encourages the use of PFS2, defined as time from initial study randomization to 2nd disease progression or death from any cause. The surrogacy of PFS2 for OS has not been confirmed. This analysis used published data from solid tumor clinical studies to assess whether PFS2 and OS are correlated.
Methods
A systematic literature search identified solid tumor oncology studies that included data for PFS, PFS2, and OS. Two independent reviewers screened titles, abstracts and main-text of study reports for eligibility, and collected data on median time to PFS2, PFS or time from 1st progression to 2nd disease progression or death, and median time to OS. The correlation between PFS2 and OS was assessed and verified in two steps: (1) Kendall’s Tau (Kendall rank correlation coefficient) statistics and Pearson’s correlation coefficient in randomized controlled trials (RCTs); (2) Meta-analysis with the random effects model to compute the pooled correlation of PFS2 and OS.
Results
In total, 133 studies met the search criteria and 15 trials had complete PFS2 and OS data (28 individual treatment and control arms) in ovarian, gastric, colorectal, prostate, lung, renal and breast tumors. A positive correlation was observed between PFS2 and OS (Kendall’s Tau = 0.7 (95% CIs 0.54, 0.78) using all 15 studies. Data from the 10 RCTs showed a Pearson’s correlation coefficient = 0.86. An additional meta-analysis of 3 tumors (breast, colorectal, and lung cancer), where more than 1 study per indication was available (7 studies; 17 individual arms), identified a Spearman’s correlation coefficient = 0.84 (p = 0.0001; 95% CIs 0.71, 0.96).
Conclusions
In this retrospective analysis in solid tumors, PFS2 was positively correlated with OS. The strong correlation provides confidence in using PFS2 as a surrogate for OS before OS data are mature or when OS cannot be assessed.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Ann C Sherwood, PhD with funding from Janssen Pharmaceuticals.
Legal entity responsible for the study
Janssen Pharmaceuticals.
Funding
Janssen Pharmaceuticals.
Disclosure
P.N. Mainwaring: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Licensing / Royalties: XING Technologies P/L; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer. L. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. S.D. Mundle: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. K. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. E. Pollozi: Shareholder / Stockholder / Stock options, Full / Part-time employment: IDEA Pharma; Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer; Advisory / Consultancy: Janssen. A. Gray: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: IDEA Pharma; Advisory / Consultancy: Janssen. M. Wildgust: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract